Treatment of autoimmune hemolytic anemias

Haematologica

Volumn 99, Issue 10, 2014, Pages 1547-1554

  Zanella, Alberto ^a   Barcellini, Wilma ^a  

^a FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ALPHA INTERFERON; AZATHIOPRINE; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CLADRIBINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DANAZOL; FLUDARABINE; FOLIC ACID; IMMUNOGLOBULIN; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OFATUMUMAB; PREDNISONE; RITUXIMAB; VITAMIN D; IMMUNOSUPPRESSIVE AGENT;

AUTOIMMUNE HEMOLYTIC ANEMIA; DRUG EFFICACY; DRUG MEGADOSE; ERYTHROCYTE TRANSFUSION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMOLYSIS; HUMAN; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; PHASE 2 CLINICAL TRIAL (TOPIC); REVIEW; SPLENECTOMY; ANEMIA, HEMOLYTIC, AUTOIMMUNE;

ANEMIA, HEMOLYTIC, AUTOIMMUNE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; SPLENECTOMY;

EID: 84907563024     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2014.114561     Document Type: Review

References (101)

1. Petz LD, Garratty G. Immune Hemolytic Anemias. 2nd ed. Philadelphia: Churchill Livingstone; 2004.
2. Lechner K, Jager U. How I treat autoimmune hemolytic anemias in adults. Blood. 2010;16: 1831-8.
3. Valent P, Lechner K. Diagnosis and treatment of autoimmune haemolytic anaemias in adults: a clinical review. Wien Klin Wochenschr. 2008;120:136-51.
4. Silberstein LE, Cunningham MJ. Autoimmune Hemolytic Anemias. In: Hillyer CD, Silberstein LE, Ness PM, Anderson KC, Roback JD (eds). Blood Banking and Transfusion Medicine. Basic Principles and Practice. 2nd ed. Philadelphia: Churchill Livingstone; 2007.
5. Aladjidi N, Leverger G, Leblanc T, Picat MQ, Michel G, Bertrand Y, et al. New insights into childhood autoimmune hemolytic anemia: a French national observational study of 265 children. Haematologica. 2011;96: 655-63.
6. Arndt PA, Leger RM, Garratty G. Serologic findings in autoimmune hemolytic anemia associated with immunoglobulin M warm autoantibodies. Transfusion. 2009;49:235-42.
7. Kamesaki T, Toyotsuji T, Kajii E. Characterization of direct antiglobulin testnegative autoimmune hemolytic anemia: a study of 154 cases. Am J Hematol. 2013; 88:93-6.
8. Liesveld JL, Rowe JM, Lichtman MA. Variability of the erythrocyte response in autoimmune hemolytic anemias: analysis of 109 cases. Blood. 1987;69:820-6.
9. Conley CL, Lippman SM, Ness P. Autoimmune hemolytic anemia with reticulocytopenia. A medical emergency. JAMA. 1980;244:1688-90.
10. Birgens H, Frederiksen H, Hasselbalch HC, Rasmussen IH, Nielsen OJ, Kjeldsen L, et al. A phase III randomized trial comparing glucocorticoid monotherapy versus glucocorticoid and rituximab in patients with autoimmune haemolytic anaemia. Br J Haematol. 2013;163:393-9.
11. Berentsen S, Ulvestad E, Gjertsen BT, Hjorth-Hansen H, Langholm R, Knutsen H, et al. Rituximab for primary chronic cold agglutinin disease: a prospective study of 37 courses of therapy in 27 patients. Blood. 2004;103:2925-8.
12. Schöllkopf C, Kjeldsen L, Bjerrum OW, Mourits-Andersen HT, Nielsen JL, Christensen BE, et al. Rituximab in chronic cold agglutinin disease: a prospective study of 20 patients. Leuk Lymphoma. 2006;47:253-60.
13. Gómez-Almaguer D, Solano-Genesta M, Tarín-Arzaga L, Herrera-Garza JL, Cantú-Rodríguez OG, Gutiérrez-Aguirre CH, et al. Low-dose rituximab and alemtuzumab combination therapy for patients with steroid-refractory autoimmune cytopenias. Blood. 2010;116:4783-5.
14. Barcellini W, Zaja F, Zaninoni A, Imperiali FG, Battista ML, Di Bona E, et al. Low-dose rituximab in adult patients with idiopathic autoimmune hemolytic anemia: clinical efficacy and biological studies. Blood. 2012;119:3691-7.
15. Barcellini W, Zaja F, Zaninoni A, Imperiali FG, Di Bona E, Fattizzo B, et al. Sustained response to low-dose rituximab in idiopathic autoimmune hemolytic anemia. Eur J Haematol. 2013;91:546-51.
16. Naithani R, Agrawal N, Mahapatra M, Kumar R, Pati HP, Choudhry VP. Autoimmune hemolytic anemia in children. Pediatr Hematol Oncol. 2007;24:309-15.
17. Gupta V, Shukla J, Bhatia BD. Autoimmune Hemolytic Anemia. Ind J Ped. 2008;75:451-4.
18. Dussadee K, Taka O, Thedsawad A, Wanachiwanawin W. Incidence and risk factors of relapses in idiopathic autoimmune hemolytic anemia. J Med Assoc Thai. 2010;93(Suppl 1):S165-S170.
19. Meyer O, Stahl D, Beckhove P, Huhn D, Salama A. Pulsed high-dose dexamethasone in chronic autoimmune haemolytic anaemia of warm type. Br J Haematol. 1997;98:860-2.
20. Ozsoylu F. Megadose methylprednisolone for the treatment of patients with Evans syndrome. Pediatr Hematol Oncol. 2004;21: 739-40.
21. Akpek G, McAneny D, Weintraub L. Comparative response to splenectomy in Coombs-positive auto-immune hemolytic anemia with or without associated disease. Am J Hematol. 1999;61:98-102.
22. Barros MM, Blajchman MA, Bordin JO. Warm autoimmune hemolytic anemia: recent progress in understanding the immunobiology and the treatment. Transf Med Rev. 2010;24:195-210.
23. Jaime-Pérez JC, Rodriguez-Martinez M, Gomez-de-Léon A, Tarin-Arzaga L, Gomez-Almaguer D. Current approaches for the treatment of autoimmune hemolytic anemia. Arch Immunol Ther Exp. 2013; 61:385-95.
24. Crowther M, Chan YL, Garbett IK, Lim W, Vickers MA, Crowther MA. Evidence-based focused review of the treatment of idiopathic warm immune hemolytic anemia in adults. Blood. 2011;118:4036-40.
25. Casaccia M, Torelli P, Squarcia S, Sormani MP, Savelli A, Troilo BM, et al. Laparoscopic splenectomy for hematologic diseases: a preliminary analysis performed on the Italian Registry of Laparoscopic Surgery of the Spleen (IRLSS). Surg Endosc. 2006;20:1214-20.
26. Bisharat N, Omari H, Lavi I, Raz R. Risk of infection and death among post-splenectomy patients. J Infect. 2001;43: 182-6.
27. Davidson RN, Wall RA. Prevention and management of infections in patients without a spleen. Clin Microbiol Infect. 2001;7:657-60.
28. Newland A, Provan D, Myint S. Preventing severe infection after splenectomy. BMJ. 2005;331:417-8.
29. Krauth MT, Lechner K, Neugebauer EA, Pabinger I. The post-operative splenic/portal vein thrombosis after splenectomy and its prevention-an unresolved issue. Haematologica. 2008;93:1227-32.
30. Pepke-Zaba J, Delcroix M, Lang I, Mayer E, Jansa P, Ambroz D, et al. Chronic thromboembolic pulmonary hypertension (CTEPH): results from an international prospective registry. Circulation. 2011;124:1973-81.
31. Garvey B. Rituximab in the treatment of autoimmune haematological disorders. Br J Haematol. 2008;14:149-69.
32. Barcellini W, Zanella A. Rituximab therapy for autoimmune haematological diseases. Eur J Intern Med. 2011;22:220-9.
33. Dierickx D, Verhoef G, Van Hoof A, Mineur P, Roest A, Triffet A, et al. Rituximab in autoimmune haemolytic anaemia and immune thrombocytopenic purpura: a Belgian retrospective multicentric study. J Intern Med. 2009;266:484-91.
34. Peñalver FJ, Alvarez-Larrán A, Díez-Martin JL, Gallur L, Jarque I, Caballero D, et al. Rituximab is an effective and safe therapeutic alternative in adults with refractory and severe autoimmune hemolytic anemia. Ann Hematol. 2010;89:1073-80.
35. Zecca M, Nobili B, Ramenghi U, Perrotta S, Amendola G, Rosito P, et al. Rituximab for the treatment of refractory autoimmune hemolytic anemia in children. Blood. 2003;101: 3857-61.
36. Narat S, Gandla J, Hoffbrand AV, Hughes RG, Mehta AB. Rituximab in the treatment of refractory autoimmune cytopenias in adults. Haematologica. 2005;90:1273-4.
37. D'Arena G, Laurenti L, Capalbo S, D'Arco AM, De Filippi R, Marcacci G, et al. Rituximab therapy for chronic lymphocytic leukemia-associated autoimmune hemolytic anemia. Am J Hematol. 2006;81:598-602.
38. Zaja F, Vianelli N, Sperotto A, Patriarca F, Tani M, Marin L, et al. Anti-CD20 therapy for chronic lymphocytic leukemia-associated autoimmune diseases. Leuk Lymphoma. 2003; 44:1951-5.
39. Maung SW, Leahy M, O'Leary HM, Khan I, Cahill MR, Gilligan O, et al. A multi-center retrospective study of rituximab use in the treatment of relapsed or resistant warm hemolytic anemia. Br J Haematol. 2013;163: 118-22.
40. Rao A, Kelly M, Musselman M, Ramadas J, Wilson D, Grossman W, et al. Safety, efficacy, and immune reconstitution after rituximab therapy in pediatric patients with chronic or refractory hematologic autoimmune cytopenias. Pediatr Blood Cancer. 2008;50:822-5.
41. Norton A, Roberts I. Management of Evans syndrome. Br J Haematol. 2006;132:125-37.
42. Bader-Meunier B, Aladjidi N, Bellmann F, Monpoux F, Nelken B, Robert A, et al. Rituximab therapy for childhood Evans syndrome. Haematologica. 2007;92:1691-4.
43. Rodella E, Pacquola E, Bianchini E, Ramazzina E, Paolini R. Consolidation treatment with rituximab induces complete and persistent remission of mixed type Evans syndrome. Blood Coagul Fibrinolysis. 2008;19:315-8.
44. Michel M, Chanet V, Dechartres A, Morin AS, Piette JC, Cirasino L, et al. The spectrum of Evans syndrome in adults: new insight into the disease based on the analysis of 68 cases. Blood. 2009;114:3167-72.
45. Bussone G, Ribeiro E, Dechartres A, Viallard JF, Bonnotte B, Fain O, et al. Efficacy and safety of rituximab in adults' warm antibody autoimmune haemolytic anemia: retrospective analysis of 27 cases. Am J Hematol. 2009;84:153-7.
46. Marzano A, Angelucci E, Andreone P, Brunetto M, Bruno R, Burra P, et al. Prophylaxis and treatment of hepatitis B in immunocompromised patients. Dig Liver Dis. 2007;39:397-408.
47. Provan D, Butler T, Evangelista ML, Amadori S, Newland AC, Stasi R. Activity and safety profile of low-dose rituximab for the treatment of autoimmune cytopenias in adults. Haematologica. 2007;92:1695-8.
48. Emilia G, Messora C, Longo G, Bertesi M. Long-term salvage treatment by cyclosporin in refractory autoimmune haematological disorders. Br J Haematol. 1996;93:341-4.
49. Liu H, Shao Z, Jing L. The effectiveness of cyclosporin A in the treatment of autoimmune hemolytic anemia and Evans syndrome. Zhonghua Xue Ye Xue Za Zhi. 2001;22:581-3.
50. Zhang Y, Chu Y, Chen G. Clinical analysis of 164 cases Coombs test positive autoimmune haemolytic anemia. Zhonghua Xue Ye Xue Za Zhi. 1998;19:573-5.
51. Alba P, Karim MY, Hunt BJ. Mycophenolate mofetil as a treatment for autoimmune haemolytic anaemia in patients with systemic lupus erythematosus and antiphospholipid syndrome. Lupus. 2003;12:633-5.
52. Howard J, Hoffbrand AV, Prentice HG, Mehta A. Mycophenolate mofetil for the treatment of refractory auto-immune haemolytic anemia and auto-immune thrombocytopenic purpura. Br J Haematol. 2002;117:712-5.
53. Lin JT, Wang WS, Yen CC, Chiou TJ, Liu JH, Hsiao LT, et al. Myelodysplastic syndrome complicated by autoimmune hemolytic anemia: remission of refractory anemia following mycophenolate mofetil. Ann Hematol. 2002;81:723-6.
54. Kotb R, Pinganaud C, Trichet C, Lambotte O, Dreyfus M, Delfraissy JF, et al. Efficacy of mycophenolate mofetil in adult refractory auto-immune cytopenias: a single center preliminary study. Eur J Haematol. 2005; 75:60-4.
55. Rao VK, Dugan F, Dale JK, Davis J, Tretler J, Hurley JK, et al. Use of mycophenolate mofetil for chronic, refractory immune cytopenias in children with autoimmune lymphoproliferative syndrome. Br J Haematol. 2005;129:534-8.
56. O'Connell N, Goodyer M, Gleeson M, Storey L, Williams M, Cotter M, et al. Successful treatment with rituximab and mycophenolate mofetil of refractory autoimmune hemolytic anemia posthematopoietic stem cell transplant for dyskeratosis congenita due to TINF2 mutation. Pediatr Transplant. 2014;18(1):E22-24.
57. Ahn YS. Efficacy of danazol in hematologic disorders. Acta Haematol 1990;84:122-9.
58. Pignon JM, Poirson E, Rochant H. Danazol in autoimmune haemolytic anaemia. Br J Haematol. 1993;83:343-5.
59. Genty I, Michel M, Hermine O, Schaeffer A, Godeau B, Rochant H. Caractéristiques des anémies hémolytiques auto-immunes de l'adulte. Analyse rétrospective d'une série de 83 patients. Rev Méd Interne. 2002;23:901-9.
60. Darabi K, Abdel-Wahab O, Dzik WH. Current usage of intravenous immune globulin and the rationale behind it: the Massachusetts General Hospital data and a review of the literature. Transfusion. 2006; 46:741-53.
61. Besa EC. Rapid transient reversal of anemia and long-term effects of maintenance intravenous immunoglobulin for autoimmune hemolytic anemia in patients with lymphoproliferative disorders. Am J Med. 1988;84: 691-8.
62. Flores G, Cunningham-Rundles C, Newland AC, Bussel JB. Efficacy of intravenous immunoglobulin in the treatment of autoimmune hemolytic anemia: results in 73 patients. Am J Hematol. 1993;44:237-42.
63. Anderson D, Ali K, Blanchette V, Brouwers M, Couban S, Radmoor P, et al. Guidelines on the use of intravenous immune globulin for hematologic conditions. Transfus Med Rev. 2007;21(Suppl 1):S9-S56.
64. McLeod BC, Strauss RG, Ciavarella D, Gilcher RO, Kasprisin DO, Kiprov DD, et al. Management of hematological disorders and cancer. J Clin Apher. 1993;8:211-30.
65. Ruivard M, Tournilach O, Montel S, Fouilhoux AC, Quainon F, Lénat A, et al. Plasma exchanges do not increase red blood cell transfusion efficiency in severe autoimmune hemolytic anemia: a retrospective case-control study. J Clin Apher. 2006;21:202-6.
66. Smith JW, Weinstein R; for the AABB Hemapheresis Committee: Therapeutic Apheresis: A summary of current indication categories endorsed by the AABB and the American Society for Apheresis. Transfusion. 2003;43:820-2.
67. Moyo VM, Smith D, Brodsky I, Crilley P, Jones RJ, Brodsky RA. High-dose cyclophosphamide for refractory autoimmune hemolytic anemia. Blood. 2002;100: 704-6.
68. Cheung WW, Hwang GY, Tse E, Kwong YL. Alemtuzumab induced complete remission of autoimmune hemolytic anemia refractory to corticosteroids, splenectomy and rituximab. Haematologica. 2006;91(Suppl 5):ECR13.
69. Willis F, Marsh JC, Bevan DH, Killick SB, Lucas G, Griffiths R, et al. The effect of treatment with Campath-1H in patients with autoimmune cytopenias. Br J Haematol. 2001;114:891-8.
70. Osterborg A, Karlsson C, Lundin J. Alemtuzumab to treat refractory autoimmune hemolytic anemia or thrombocytopenia in chronic lymphocytic leukemia. Curr Hematol Malig Rep. 2009;4:47-53.
71. Karlsson C, Hansson L, Celsing F, Lundin J. Treatment of severe refractory autoimmune hemolytic anemia in B-cell chronic lymphocytic leukemia with alemtuzumab (humanized CD52 monoclonal antibody). Leukemia. 2007;21:511-4.
72. Laurenti L, Tarnani M, Efremov DG, Chiusolo P, De Padua L, Sica S, et al. Efficacy and safety of low-dose alemtuzumab as treatment of autoimmune hemolytic anemia in pretreated B-cell chronic lymphocytic leukemia. Leukemia. 2007;21:1819-21.
73. Nader K, Patel M, Ferber A. Ofatumumab in rituximab-refractory autoimmune hemolytic anemia associated with chronic lymphocytic leukemia: a case report and review of literature. Clin Lymphoma Myeloma Leuk. 2013;13:511-3
74. Urban C, Lackner H, Sovinz P, Benesch M, Schwinger W, Dornbusch HJ, et al. Successful unrelated cord blood transplantation in a 7-year-old boy with Evans syndrome refractory to immunosuppression and double autologous stem cell transplantation. Eur J Haematol. 2006;76:526-30.
75. Passweg JR, Rabusin M. Hematopoietic stem cell transplantation for immune thrombocytopenia and other refractory autoimmune cytopenias. Autoimmunity. 2008;41:660-5.
76. Snowden JA, Saccardi R, Allez M, Ardizzone S, Arnold R, Cervera R, et al. Haematopoietic SCT in severe autoimmune diseases: updated guidelines of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant. 2012;47:770-90.
77. El Kenz H, Efira A, Le PQ, Thiry C, Valsamis J, Azerad MA, et al. Transfusion support of autoimmune hemolytic anemia: how could the blood group genotyping help? Transl Res. 2014;163:36-42.
78. King KE, Ness PM. Treatment of autoimmune hemolytic anemia. Semin Hematol. 2005;42:131-6.
79. Sokol RJ, Hewitt S, Booker DJ, Morris BM. Patients with red cell autoantibodies: selection of blood for transfusion. Clin Lab Haematol. 1988;10:257-64.
80. Yu Y, Sun XL, Ma CY, Guan XZ, Zhang XJ, Chen LF, et al. Serological characteristics and transfusion efficacy evaluation in 61 cases of autoimmune hemolytic anemia. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2013;21:1275-9.
81. Wouters D, Stephan F, Strengers P, de Haas M, Brower C, Hagenbeek A, et al. C1-esterase inhibitor concentrate rescues erythrocytes from complement-mediated destruction in autoimmune hemolytic anemia. Blood. 2013;121:1242-4.
82. Arbach O, Funck R, Seibt F, Salama A. Erythropoietin may improve anemia in patients with autoimmune hemolytic anemia associated with reticulocytopenia. Transfus Med Hemother. 2012;39:221-3.
83. Berentsen S. How I manage cold agglutinin disease. Br J Haematol. 2011;153:309-17.
84. Berentsen S, Tjønnfjord GE. Diagnosis and treatment of cold agglutinin mediated autoimmune hemolytic anemia. Blood Reviews. 2012;26:107-15.
85. Gertz MA. Management of cold haemolytic syndrome. Br J Haematol. 2007;138:422-9.
86. Schreiber AD, Herskovitz BS, Goldwein M. Low-titer cold-hemagglutinin disease. Mechanism of hemolysis and response to corticosteroids. N Engl J Med. 1977;296: 1490-4.
87. Berentsen S, Ulvestad E, Langholm R, Beiske K, Hjorth-Hansen H, Ghanima W, et al. Primary chronic cold agglutinin disease: a population based clinical study of 86 patients. Haematologica. 2006;91:460-6.
88. Hippe E, Jensen KB, Olesen H, Lind K, Thomsen PE. Chlorambucil treatment of patients with cold agglutinin syndrome. Blood. 1970;35:68-72.
89. Chandesris MO, Schleinitz N, Ferrera V, Bernit E, Mazodier K, Gayet S, et al. Cold agglutinins, clinical presentation and significance: retrospective analysis of 58 patients. Rev Med Interne. 2004;25:856-65.
90. Berentsen S, Tjonnfjord GE, Shammas FV, Bergheim J, Hammerstrom J, Langholm R, et al. No response to cladribine in five patients with chronic cold agglutinin disease. Eur J Haematol. 2000;65:88-90.
91. Swiecicki PL, Hegerova LT, Gertz MA. Cold agglutinin disease. Blood. 2013;122:1114-21.
92. Berentsen S, Randen U, Vagan AM, Hjorth-Hansen H, Vik A, Dalgaard J, et al. High response rate and durable remissions following fludarabine and rituximab combination therapy for chronic cold agglutinin disease. Blood. 2010;116:3180-4.
93. Zoppi M, Oppliger R, Althaus U, Nydegger U. Reduction of plasma cold agglutinin titers by means of plasmapheresis to prepare a patient for coronary bypass surgery. Infusionsther Transfusionsmed. 1993;20: 19-22.
94. Pecsi SA, Almassi GH, Langenstroer P. Deep hypothermic circulatory arrest for a patient with known cold agglutinins. Ann Thorac Surg. 2009;88:1326-7.
95. Carson KR, Beckwith LG, Mehta J. Successful treatment of IgM-mediated autoimmune hemolytic anemia with bortezomib. Blood. 2010;115:915.
96. Roth A, Huttmann A, Rother RP, Duhrsen U, Philipp T. Long-term efficacy of the complement inhibitor eculizumab in cold agglutinin disease. Blood. 2009;113:3885-6.
97. Bommer M, Hochsmann B, Flegel WA, Doehner H, Schrezenmeier H. Successful treatment of complement mediated refractory haemolysis associated with cold and warm autoantibodies using eculizumab abstract. Haematologica. 2009;94(Suppl 2):241-2. Abstract 0593.
98. Sokol RJ, Hewitt S, Stamps BK. Autoimmune haemolysis associated with Donath-Landsteiner antibodies. Acta Haematol. 1982;68:268-77.
99. Gregory GP, Opat S, Quach H, Shortt J, Tran H. Failure of eculizumab to correct paroxysmal cold hemoglobinuria. Ann Hematol. 2011;90:989-90.
100. Shulman IA, Branch DR, Nelson JM, Thompson JC, Saxena S, Petz LD. Autoimmune hemolytic anemia with both cold and warm autoantibodies. JAMA. 1985;253:1746-8.
101. Nusbaum NJ, Khosla S. Autoimmune hemolytic anemia with both cold and warm autoantibodies. JAMA. 1985;254:1175-6.